<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: TNF-alpha levels are increased in <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The regulation of TNF-alpha converting enzyme (TACE) and its inhibitor, tissue inhibitor of metalloproteinase 3 (TIMP3), in human type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We examined TACE/TIMP3 regulation: (1) in lean and <z:mp ids='MP_0001261'>obese</z:mp> <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerant (NGT) individuals and in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients; (2) following 6 h of <z:chebi fb="23" ids="18059">lipid</z:chebi>/saline infusion in NGT individuals; and (3) in cultured human myotubes from lean NGT individuals incubated with <z:chebi fb="2" ids="29889">palmitate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin sensitivity was assessed by a euglycaemic clamp and TACE/TIMP3 was evaluated by confocal microscopy, RT-PCR, western blotting and an in vitro activity assay </plain></SENT>
<SENT sid="4" pm="."><plain>Circulating TNF-alpha, TNF-alpha-receptor 1 (TNFR1), TNF-alpha-receptor 2 (TNFR2), IL-6 receptor (IL-6R), vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (VCAM) and intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (ICAM) levels were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: TIMP3 levels were reduced and TACE enzymatic activity was increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> skeletal muscle </plain></SENT>
<SENT sid="6" pm="."><plain>TACE expression, and TACE, TNF-alpha, TNFR1 and IL-6R levels were increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and positively correlated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>A 6 h <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion into NGT individuals decreased insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism by 25% with increased TACE, decreased expression of the gene encoding TIMP3 and increased IL-6R release </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="2" ids="29889">Palmitate</z:chebi> induced a dramatic reduction of TIMP3 and increased the TACE/TIMP3 ratio in cultured myotubes </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: TACE activity was increased in skeletal muscle of <z:mp ids='MP_0001261'>obese</z:mp> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients and in <z:chebi fb="23" ids="18059">lipid</z:chebi>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>We propose that dysregulation of membrane proteolysis by TACE/TIMP3 of TNF-alpha and IL-6R is an important factor for the development of skeletal muscle <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in <z:mp ids='MP_0001261'>obese</z:mp> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients by a novel autocrine/paracrine mechanism </plain></SENT>
</text></document>